Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Opioid Combination

Therapeutic area intelligence for Opioid Combination with 18 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 18
Catalysts: 0
Companies: 6

Companies

Amneal Pharmaceuticals →

ANI Pharmaceuticals →

Rhodes Pharmaceuticals →

Strides Pharma →

Strides Pharma Intl →

Assets

Recent signals(18)

Regulatory

June 29, 2026

FDA Approval Update for Hydrocodone Bitartrate and Ibuprofen by Amneal Pharmaceuticals

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination of hydrocodone bitartrate and ibuprofen by Amneal Pharmaceuticals.

RegulatoryJune 28, 2026

FDA Approval Letter for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen by Rhodes Pharmaceuticals.

RegulatoryJune 28, 2026

FDA Approval Update for Oxycodone and Acetaminophen by Lannett Co Inc

Lannett Co Inc has received an approval status for their ANDA submission for Oxycodone and Acetaminophen.

RegulatoryJune 28, 2026

FDA Approval Update for Hydrocodone Bitartrate and Acetaminophen by Strides Pharma

The FDA has granted an approval status (AP) for the ANDA040355 application for Hydrocodone Bitartrate and Acetaminophen submitted by Strides Pharma.

RegulatoryJune 28, 2026

FDA Approval Status for Acetaminophen and Codeine Phosphate (ANDA211610)

The FDA has granted an approval status of 'AP' for ANDA211610, a combination of acetaminophen and codeine phosphate.

RegulatoryJune 28, 2026

FDA Approval of Hydrocodone Bitartrate and Acetaminophen Supplement

The FDA has approved a supplemental application for Hydrocodone Bitartrate and Acetaminophen under ANDA205001 by Strides Pharma Intl.

RegulatoryJune 28, 2026

FDA Grants AP Status for OXYCET (ANDA087463) by SPECGX LLC

The FDA has granted Abbreviated Approval (AP) status for OXYCET, a combination of acetaminophen and oxycodone hydrochloride, submitted by SPECGX LLC.

StrategyJune 28, 2026

FDA Approval Update for Hydrocodone Bitartrate and Acetaminophen by SPECGX LLC

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Hydrocodone Bitartrate and Acetaminophen submitted by SPECGX LLC.

RegulatoryJune 28, 2026

FDA Approval for ANEXSIA 7.5/325 by SPECGX LLC

The FDA has granted approval for ANEXSIA 7.5/325, a combination of acetaminophen and hydrocodone bitartrate.

RegulatoryJune 28, 2026

FDA Approves Supplemental Application for Oxycodone and Acetaminophen

The FDA has approved a supplemental application for a combination product containing oxycodone hydrochloride and acetaminophen.

RegulatoryJune 27, 2026

FDA Approval Update for Oxycodone Hydrochloride and Acetaminophen

The FDA has issued an approval letter for ANDA203573, a combination of oxycodone hydrochloride and acetaminophen.

RegulatoryJune 26, 2026

FDA Accepts Supplement Application for Oxycodone and Acetaminophen

The FDA has accepted the supplemental application for a combination product of oxycodone hydrochloride and acetaminophen submitted by Mikart.

StrategyJune 25, 2026

FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen

The FDA has issued an approval letter for ANDA207137, a combination of hydrocodone bitartrate and acetaminophen.

RegulatoryJune 24, 2026

FDA Approval Update for Oxycodone and Acetaminophen Supplement

The FDA has issued an approval letter for the supplement application of Oxycodone and Acetaminophen submitted by Actavis Elizabeth.

RegulatoryJune 24, 2026

FDA Accepts Supplemental Application for Percodan by Endo Operations

The FDA has accepted a supplemental application for Percodan, which contains aspirin and oxycodone hydrochloride.

RegulatoryJune 24, 2026

ANI Pharmaceuticals submits supplemental application for Oxycodone and Aspirin

ANI Pharmaceuticals has submitted a supplemental application for a combination product containing Oxycodone and Aspirin.

RegulatoryJune 24, 2026

FDA Approval Letter for Oxycodone and Aspirin Combination

The FDA has issued an approval letter for ANDA040260 concerning a combination of oxycodone and aspirin.

StrategyJune 24, 2026

FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen

The FDA has issued an approval letter for ANDA206869, a combination of hydrocodone bitartrate and acetaminophen.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.